Patents by Inventor Baohui HAN

Baohui HAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF TREATING CANCER USING A COMBINATION OF QUINOLINE DERIVATIVE AND ANTIBODY
    Publication number: 20260097030
    Abstract: The present application provides a therapeutic combination of a quinoline derivative and an antibody, which comprises an immune checkpoint inhibitor and a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is a compound of formula I or a pharmaceutically acceptable salt thereof. The therapeutic combination in the present application shows good activity against lung tumor and liver tumor.
    Type: Application
    Filed: April 11, 2025
    Publication date: April 9, 2026
    Inventors: Xin TIAN, Chen SHEN, Peng LYU, Xiangjian WANG, Xiquan ZHANG, Zheng LIU, Yu XIA, Xiaoping JIN, Baiyong LI, Zhongmin Maxwell WANG, Baohui HAN, Tianqing CHU, Hua ZHONG, Rong LI
  • Therapeutic combination of quinoline derivative and antibody
    Patent number: 12390458
    Abstract: The present application provides a therapeutic combination of a quinoline derivative and an antibody, which comprises an immune checkpoint inhibitor and a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is a compound of formula I or a pharmaceutically acceptable salt thereof. The therapeutic combination in the present application shows good activity against lung tumor and liver tumor.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: August 19, 2025
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Xin Tian, Chen Shen, Peng Lyu, Xiangjian Wang, Xiquan Zhang, Zheng Liu, Yu Xia, Xiaoping Jin, Baiyong Li, Zhongmin Maxwell Wang, Baohui Han, Tianqing Chu, Hua Zhong, Rong Li
  • THERAPEUTIC COMBINATION OF QUINOLINE DERIVATIVE AND ANTIBODY
    Publication number: 20220160700
    Abstract: The present application provides a therapeutic combination of a quinoline derivative and an antibody, which comprises an immune checkpoint inhibitor and a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is a compound of formula I or a pharmaceutically acceptable salt thereof. The therapeutic combination in the present application shows good activity against lung tumor and liver tumor.
    Type: Application
    Filed: July 18, 2019
    Publication date: May 26, 2022
    Inventors: Xin TIAN, Chen SHEN, Peng LYU, Xiangjian WANG, Xiquan ZHANG, Zheng LIU, Yu XIA, Xiaoping JIN, Baiyong LI, Zhongmin Maxwell WANG, Baohui HAN, Tianqing CHU, Hua ZHONG, Rong LI